Search Results

ERS Genomics Limited, the CRISPR licensing company, announced the appointment of John E Milad as CEO, with immediate effect.

ERS Genomics Limited, the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, announced a non-exclusive CRISPR/Cas9 license agreement.

Ricoh Company, Ltd. announced a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.

ERS Genomics Limited, the CRISPR licensing Company, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and StemSight Oy, a biotechnology company developing stem cell based therapies for corneal blindness, announced a non-exclusive CRISPR/Cas9 license agreement.

Dovetail Genomics, a pioneering leader in the development of genomic solutions, announced a new strategic partnership with Australian Genome Research Facility.

Reveal Genomics ® HER2DX ® Genomic Test Demonstrates Significant Potential in HER2-Positive Advanced Gastric Cancer.

Reveal Genomics® to Evaluate Prospective Real-time Performance of HER2DX ® Genomic Test in the United States.

Dovetail Genomics announces the Dovetail® AssemblyLink™ Assay, a transformative genomics tool designed to redefine the standards of speed and quality in genomic assembly.

Collegium Pharmaceutical, Inc. today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta ® ER.

Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence -enabled drug discovery, announced data from an ongoing Phase 1 study of AC699 monotherapy in patients with ER-positive / HER2-negative locally advanced or metastatic breast cancer.